Novavax (NVAX) says its respiratory syncytial virus vaccine met objectives in a Phase II...

|By:, SA News Editor

Novavax (NVAX) says its respiratory syncytial virus vaccine met objectives in a Phase II clinical trial. The company says the drug was well-tolerated and there "were no clinically important differences in systemic adverse events between placebo and active vaccine recipients." Shares +7% AH.